flosz schreef op 29 september 2014 11:37:
Ebola outbreak: EMA to review experimental medicines to support treatment decisions
The companies identified so far include:
Biocryst, a US-based company developing BCX 4430
Fab’entech, from France, developing Hyperimmune horse sera
MAPP Biologicals, a US-based company developing ZMAPP
Sarepta, a US company developing Sarepta AVI-7537
Toyama Chemicals, Fujifilm Group, based in Japan and MediVector Inc, based in the US, who are jointly developing Favipiravir
Tekmira, a Canadian company developing TKM-Ebola
Companies that are not included in the list above but are also developing Ebola treatments are encouraged to contact the EMA.